Evidence map›Paper›PMID 29305543›Full record

ArticleJournal of clinical microbiology2018

Genotyping Multidrug-Resistant Mycobacterium tuberculosis from Primary Sputum and Decontaminated Sediment with an Integrated Microfluidic Amplification Microarray Test.

Yvonne Linger, Christopher Knickerbocker, David Sipes, Julia Golova, Molly Franke, Roger Calderon, Leonid Lecca, Nitu Thakore, Rebecca Holmberg, Peter Qu and 4 more

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Yvonne LingerAkonni Biosystems, Inc., Frederick, Maryland, USA.
Christopher KnickerbockerAkonni Biosystems, Inc., Frederick, Maryland, USA.
David SipesAkonni Biosystems, Inc., Frederick, Maryland, USA.
Julia GolovaAkonni Biosystems, Inc., Frederick, Maryland, USA.
Molly FrankeHarvard Medical School, Department of Global Health and Social Medicine, Boston, Massachusetts, USA.
Roger CalderonSocios En Salud Sucursal Perú, Lima, Peru.
Leonid LeccaHarvard Medical School, Department of Global Health and Social Medicine, Boston, Massachusetts, USA.
Nitu ThakoreAkonni Biosystems, Inc., Frederick, Maryland, USA.
Rebecca HolmbergAkonni Biosystems, Inc., Frederick, Maryland, USA.
Peter QuAkonni Biosystems, Inc., Frederick, Maryland, USA.
Alexander KukhtinAkonni Biosystems, Inc., Frederick, Maryland, USA.
Megan B MurrayHarvard Medical School, Department of Global Health and Social Medicine, Boston, Massachusetts, USA.
Christopher G CooneyAkonni Biosystems, Inc., Frederick, Maryland, USA.
Darrell P ChandlerAkonni Biosystems, Inc., Frederick, Maryland, USA dchandler@akonni.com.
Akonni Biosystems (United States) · USHarvard Global Health Institute · USEsSALUD · PEHarvard University · US

Funding

Sequencing CoreU19AI109755 · NIAID · HARVARD MEDICAL SCHOOL · PI CHANDLER, DARRELL P, CULHANE, AEDIN C · 2014 to 2018
$29.1M
An Integrated Tabletop Platform for Rapid Detection of XDR-TB in Clinical SamplesR01AI111435 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RODWELL, TIMOTHY CHARLES · 2014 to 2018
$5.4M
NIAID NIH HHS R01 AI111435NIAID NIH HHS U19 AI109755
6 · The paper itself

Abstract

There is a growing awareness that molecular diagnostics for detect-to-treat applications will soon need a highly multiplexed mutation detection and identification capability. In this study, we converted an open-amplicon microarray hybridization test for multidrug-resistant (MDR)

Indexed as

Oligonucleotide Array Sequence AnalysisAntitubercular AgentsDrug Resistance, Multiple, BacterialGenes, MDRGenotypeGenotyping TechniquesGeologic SedimentsHumansIsoniazidMicrobial Sensitivity TestsMicrofluidic Analytical TechniquesMycobacterium tuberculosisRifampinSensitivity and SpecificitySputumTuberculosis, Multidrug-ResistantAntitubercular AgentsIsoniazidRifampinamplification microarrayclosed amplicondrug resistancein vitro diagnosticmicrofluidicMycobacterium tuberculosis

Identifiers

PMID29305543
PMCPMC5824040
OpenAlexW2782321484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.